{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T08:28:34Z","timestamp":1794472114596,"version":"4.9.1"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,10,22]],"date-time":"2019-10-22T00:00:00Z","timestamp":1571702400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,10,22]],"date-time":"2019-10-22T00:00:00Z","timestamp":1571702400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["61721003"],"award-info":[{"award-number":["61721003"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Improving efficacy of oncolytic virotherapy remains challenging due to difficulty increasing specificity and immune responses against cancer and limited understanding of its population dynamics. Here, we construct programmable and modular synthetic gene circuits to control adenoviral replication and release of immune effectors selectively in hepatocellular carcinoma cells in response to multiple promoter and microRNA inputs. By performing mouse model experiments and computational simulations, we find that replicable adenovirus has a superior tumor-killing efficacy than non-replicable adenovirus. We observe a synergistic effect on promoting local lymphocyte cytotoxicity and systematic vaccination in immunocompetent mouse models by combining tumor lysis and secretion of immunomodulators. Furthermore, our computational simulations show that oncolytic virus which encodes immunomodulators can exert a more robust therapeutic efficacy than combinatorial treatment with oncolytic virus and immune effector. Our results provide an effective strategy to engineer oncolytic adenovirus, which may lead to innovative immunotherapies for a variety of cancers.<\/jats:p>","DOI":"10.1038\/s41467-019-12794-2","type":"journal-article","created":{"date-parts":[[2019,10,23]],"date-time":"2019-10-23T00:26:13Z","timestamp":1571790373000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":87,"title":["Oncolytic adenovirus programmed by synthetic gene circuit for cancer immunotherapy"],"prefix":"10.1038","volume":"10","author":[{"given":"Huiya","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiqi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weixi","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yubing","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yakun","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinying","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,10,22]]},"reference":[{"key":"12794_CR1","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1038\/nrd.2016.254","volume":"15","author":"E Dolgin","year":"2016","unstructured":"Dolgin, E. Cancer immunology community seeks better end points. Nat. Rev. Drug Discov. 15, 807\u2013809 (2016).","journal-title":"Nat. Rev. Drug Discov."},{"key":"12794_CR2","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/nm.4015","volume":"22","author":"CA Klebanoff","year":"2016","unstructured":"Klebanoff, C. A., Rosenberg, S. A. & Restifo, N. P. Prospects for gene-engineered T cell immunotherapy for solid cancers. Nat. Med. 22, 26\u201336 (2016).","journal-title":"Nat. Med."},{"key":"12794_CR3","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/nature14011","volume":"515","author":"RS Herbst","year":"2014","unstructured":"Herbst, R. S. et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515, 563\u2013567 (2014).","journal-title":"Nature"},{"key":"12794_CR4","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1038\/nrclinonc.2016.58","volume":"13","author":"C Boutros","year":"2016","unstructured":"Boutros, C. et al. Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination. Nat. Rev. Clin. Oncol. 13, 473\u2013486 (2016).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"12794_CR5","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1038\/nrd4663","volume":"14","author":"HL Kaufman","year":"2015","unstructured":"Kaufman, H. L., Kohlhapp, F. J. & Zloza, A. Oncolytic viruses: a new class of immunotherapy drugs. Nat. Rev. Drug Discov. 14, 642\u2013662 (2015).","journal-title":"Nat. Rev. Drug Discov."},{"key":"12794_CR6","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1006\/mthe.2000.0130","volume":"2","author":"M Toda","year":"2000","unstructured":"Toda, M., Martuza, R. L. & Rabkin, S. D. Tumor growth inhibition by intratumoral inoculation of defective herpes simplex virus vectors expressing granulocyte\u2013macrophage colony-stimulating factor. Mol. Ther. 2, 324\u2013329 (2000).","journal-title":"Mol. Ther."},{"key":"12794_CR7","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/cgt.2011.67","volume":"19","author":"X Liu","year":"2012","unstructured":"Liu, X. et al. Gene-viro-therapy targeting liver cancer by a dual-regulated oncolytic adenoviral vector harboring IL-24 and TRAIL. Cancer Gene Ther. 19, 49\u201357 (2012).","journal-title":"Cancer Gene Ther."},{"key":"12794_CR8","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1158\/1078-0432.CCR-05-1059","volume":"12","author":"N Ramesh","year":"2006","unstructured":"Ramesh, N. et al. CG0070, a conditionally replicating granulocyte macrophage colony-stimulating factor \u2212 armed oncolytic adenovirus for the treatment of bladder cancer for the treatment of bladder cancer. Clin. Cancer Res 12, 305\u2013313 (2006).","journal-title":"Clin. Cancer Res"},{"key":"12794_CR9","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1158\/0008-5472.CAN-16-1708","volume":"77","author":"CA Fajardo","year":"2017","unstructured":"Fajardo, C. A. et al. Oncolytic adenoviral delivery of an EGFR-targeting t-cell engager improves antitumor efficacy. Cancer Res. 77, 2052\u20132063 (2017).","journal-title":"Cancer Res."},{"key":"12794_CR10","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1016\/j.cell.2017.08.027","volume":"170","author":"A Ribas","year":"2017","unstructured":"Ribas, A. et al. Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy. Cell 170, 1109\u20131119.e10 (2017).","journal-title":"Cell"},{"key":"12794_CR11","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1126\/science.274.5286.373","volume":"274","author":"JR Bischoff","year":"1996","unstructured":"Bischoff, J. R. et al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 274, 373\u20136 (1996).","journal-title":"Science"},{"key":"12794_CR12","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1038\/nm.3089","volume":"19","author":"J Heo","year":"2013","unstructured":"Heo, J. et al. Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer. Nat. Med. 19, 329\u2013336 (2013).","journal-title":"Nat. Med."},{"key":"12794_CR13","doi-asserted-by":"crossref","first-page":"5911","DOI":"10.1128\/jvi.67.10.5911-5921.1993","volume":"67","author":"aJ Bett","year":"1993","unstructured":"Bett, aJ., Prevec, L. & Graham, F. L. Packaging capacity and stability of human adenovirus type 5 vectors. J. Virol. 67, 5911\u20135921 (1993).","journal-title":"J. Virol."},{"key":"12794_CR14","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1101\/gad.7.4.546","volume":"7","author":"M Debbas","year":"1993","unstructured":"Debbas, M. & White, E. Wild-type p53 mediates apoptosis by E1A, which is inhibited by E1B. Genes Dev. 7, 546\u201354 (1993).","journal-title":"Genes Dev."},{"key":"12794_CR15","doi-asserted-by":"publisher","first-page":"2410","DOI":"10.1158\/1535-7163.MCT-12-0157","volume":"11","author":"Z Zhang","year":"2012","unstructured":"Zhang, Z., Zhang, X., Newman, K. & Liu, X. MicroRNA regulation of oncolytic adenovirus 6 for selective treatment of castration-resistant prostate cancer. Mol. Cancer Ther. 11, 2410\u20138 (2012).","journal-title":"Mol. Cancer Ther."},{"key":"12794_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0073964","volume":"8","author":"E Callegari","year":"2013","unstructured":"Callegari, E. et al. Anti-Tumor Activity of a miR-199-dependent Oncolytic Adenovirus. PLoS ONE 8, 1\u201316 (2013).","journal-title":"PLoS ONE"},{"key":"12794_CR17","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1126\/science.1205527","volume":"333","author":"Z Xie","year":"2011","unstructured":"Xie, Z., Wroblewska, L., Prochazka, L., Weiss, R. & Benenson, Y. Multi-input RNAi-based logic circuit for identification of specific cancer cells. Science 333, 1307\u20131311 (2011).","journal-title":"Science"},{"key":"12794_CR18","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1038\/nm.1776","volume":"14","author":"EJ Kelly","year":"2008","unstructured":"Kelly, E. J., Hadac, E. M., Greiner, S. & Russell, S. J. Engineering microRNA responsiveness to decrease virus pathogenicity. Nat. Med. 14, 1278\u20131283 (2008).","journal-title":"Nat. Med."},{"key":"12794_CR19","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.canlet.2016.07.019","volume":"381","author":"X Yuan","year":"2016","unstructured":"Yuan, X. et al. Mesenchymal stem cells deliver and release conditionally replicative adenovirus depending on hepatic differentiation to eliminate hepatocellular carcinoma cells specifically. Cancer Lett. 381, 85\u201395 (2016).","journal-title":"Cancer Lett."},{"key":"12794_CR20","first-page":"1","volume":"5","author":"Y Liu","year":"2014","unstructured":"Liu, Y. et al. Synthesizing AND gate genetic circuits based on CRISPR-Cas9 for identification of bladder cancer cells. Nat. Commun. 5, 1\u20137 (2014).","journal-title":"Nat. Commun."},{"key":"12794_CR21","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1038\/nchembio.1680","volume":"10","author":"N Lapique","year":"2014","unstructured":"Lapique, N. & Benenson, Y. Digital switching in a biosensor circuit via programmable timing of gene availability. Nat. Chem. Biol. 10, 1020\u20131027 (2014).","journal-title":"Nat. Chem. Biol."},{"key":"12794_CR22","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1038\/nbt.3301","volume":"33","author":"L Wroblewska","year":"2015","unstructured":"Wroblewska, L. et al. Mammalian synthetic circuits with RNA binding proteins for RNA-only delivery. Nat. Biotechnol. 33, 839\u201341 (2015).","journal-title":"Nat. Biotechnol."},{"key":"12794_CR23","doi-asserted-by":"publisher","first-page":"2525","DOI":"10.1016\/j.celrep.2016.07.061","volume":"16","author":"B Angelici","year":"2016","unstructured":"Angelici, B., Mailand, E., Haefliger, B. & Benenson, Y. Synthetic Biology Platform for Sensing and Integrating Endogenous Transcriptional Inputs in Mammalian Cells. Cell Rep. 16, 2525\u201337 (2016).","journal-title":"Cell Rep."},{"key":"12794_CR24","doi-asserted-by":"publisher","first-page":"8133","DOI":"10.1073\/pnas.1604391113","volume":"113","author":"M Morel","year":"2016","unstructured":"Morel, M., Shtrahman, R., Rotter, V., Nissim, L. & Bar-Ziv, R. H. Cellular heterogeneity mediates inherent sensitivity-specificity tradeoff in cancer targeting by synthetic circuits. Proc. Natl Acad. Sci. USA 113, 8133\u20138 (2016).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"12794_CR25","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1016\/j.cell.2017.09.049","volume":"171","author":"L Nissim","year":"2017","unstructured":"Nissim, L. et al. Synthetic RNA-based immunomodulatory gene circuits for cancer immunotherapy. Cell 171, 1138\u20131150.e15 (2017).","journal-title":"Cell"},{"key":"12794_CR26","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1038\/nchembio.1736","volume":"11","author":"Y Li","year":"2015","unstructured":"Li, Y. et al. Modular construction of mammalian gene circuits using TALE transcriptional repressors. Nat. Chem. Biol. 11, 207\u2013213 (2015).","journal-title":"Nat. Chem. Biol."},{"key":"12794_CR27","volume":"7","author":"D Ma","year":"2016","unstructured":"Ma, D., Peng, S. & Xie, Z. Integration and exchange of split dCas9 domains for transcriptional controls in mammalian cells. Nat. Commun. 7, 100084 (2016).","journal-title":"Nat. Commun."},{"key":"12794_CR28","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1038\/nbt957","volume":"22","author":"AL Szymczak","year":"2004","unstructured":"Szymczak, A. L. et al. Correction of multi-gene deficiency in vivo using a single \u201cself-cleaving\u201d 2A peptide-based retroviral vector. Nat. Biotechnol. 22, 589\u2013594 (2004).","journal-title":"Nat. Biotechnol."},{"key":"12794_CR29","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1038\/cgt.2014.34","volume":"21","author":"T Du","year":"2014","unstructured":"Du, T. et al. Tumor-specific oncolytic adenoviruses expressing granulocyte macrophage colony-stimulating factor or anti-CTLA4 antibody for the treatment of cancers. Cancer Gene Ther. 21, 340\u20138 (2014).","journal-title":"Cancer Gene Ther."},{"key":"12794_CR30","doi-asserted-by":"publisher","first-page":"2780","DOI":"10.1200\/JCO.2014.58.3377","volume":"33","author":"RHI Andtbacka","year":"2015","unstructured":"Andtbacka, R. H. I. et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J. Clin. Oncol. 33, 2780\u20132788 (2015).","journal-title":"J. Clin. Oncol."},{"key":"12794_CR31","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.omto.2016.12.004","volume":"4","author":"R Havunen","year":"2017","unstructured":"Havunen, R. et al. Oncolytic adenoviruses armed with tumor necrosis factor alpha and interleukin-2 enable successful adoptive cell therapy. Mol. Ther. - Oncolytics 4, 77\u201386 (2017).","journal-title":"Mol. Ther. - Oncolytics"},{"key":"12794_CR32","doi-asserted-by":"publisher","first-page":"pii: 20170150","DOI":"10.1098\/rsif.2017.0150","volume":"14","author":"A Konstorum","year":"2017","unstructured":"Konstorum, A., Vella, A. T., Adler, A. J. & Laubenbacher, R. C. Addressing current challenges in cancer immunotherapy with mathematical and computational modelling. J. R. Soc. Interface 14, pii: 20170150 (2017).","journal-title":"J. R. Soc. Interface"},{"key":"12794_CR33","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s002850050127","volume":"37","author":"D Kirschner","year":"1998","unstructured":"Kirschner, D. & Panetta, J. C. Modeling immunotherapy of the tumor - Immune interaction. J. Math. Biol. 37, 235\u2013252 (1998).","journal-title":"J. Math. Biol."},{"key":"12794_CR34","first-page":"3501","volume":"61","author":"D Wodarz","year":"2001","unstructured":"Wodarz, D. Viruses as antitumor weapons: defining conditions for tumor remission. Cancer Res. 61, 3501\u20133507 (2001).","journal-title":"Cancer Res."},{"key":"12794_CR35","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/sj.gt.3300870","volume":"6","author":"H Ishikawa","year":"1999","unstructured":"Ishikawa, H. et al. Utilization of variant-type of human a-fetoprotein promoter in gene therapy targeting for hepatocellular carcinoma. Gene Ther. 6, 465\u2013470 (1999).","journal-title":"Gene Ther."},{"key":"12794_CR36","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.ccr.2011.01.001","volume":"19","author":"J Hou","year":"2011","unstructured":"Hou, J. et al. Identification of miRNomes in human liver and hepatocellular carcinoma reveals miR-199a\/b-3p as therapeutic target for hepatocellular carcinoma. Cancer Cell 19, 232\u2013243 (2011).","journal-title":"Cancer Cell"},{"key":"12794_CR37","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1016\/j.cell.2007.04.040","volume":"129","author":"P Landgraf","year":"2007","unstructured":"Landgraf, P. et al. A mammalian microRNA expression atlas based on small RNA library sequencing. Cell 129, 1401\u20131414 (2007).","journal-title":"Cell"},{"key":"12794_CR38","doi-asserted-by":"publisher","first-page":"e5553","DOI":"10.1371\/journal.pone.0005553","volume":"4","author":"C Engler","year":"2009","unstructured":"Engler, C., Gruetzner, R., Kandzia, R. & Marillonnet, S. Golden gate shuffling: a one-pot DNA shuffling method based on type IIs restriction enzymes. PLoS One 4, e5553 (2009).","journal-title":"PLoS One"},{"key":"12794_CR39","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1021\/acssynbio.7b00134","volume":"7","author":"W Liao","year":"2018","unstructured":"Liao, W. et al. Functional characterization of insulation effect for synthetic gene circuits in mammalian cells. ACS Synth. Biol. 7, 412\u2013418 (2018).","journal-title":"ACS Synth. Biol."},{"key":"12794_CR40","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1038\/sj.gt.3302001","volume":"10","author":"Y Nagayama","year":"2003","unstructured":"Nagayama, Y., Nakao, K., Mizuguchi, H., Hayakawa, T. & Niwa, M. Enhanced antitumor effect of combined replicative adenovirus and nonreplicative adenovirus expressing interleukin-12 in an immunocompetent mouse model. Gene Ther. 10, 1400\u20131403 (2003).","journal-title":"Gene Ther."},{"key":"12794_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms14754","volume":"8","author":"Z Liu","year":"2017","unstructured":"Liu, Z., Ravindranathan, R., Kalinski, P., Guo, Z. S. & Bartlett, D. L. Rational combination of oncolytic vaccinia virus and PD-L1 blockade works synergistically to enhance therapeutic efficacy. Nat. Commun. 8, 14754 (2017).","journal-title":"Nat. Commun."},{"key":"12794_CR42","doi-asserted-by":"publisher","first-page":"3541","DOI":"10.1200\/JCO.2015.61.6870","volume":"33","author":"VL Chiou","year":"2015","unstructured":"Chiou, V. L. & Burotto, M. Pseudoprogression and Immune-Related Response in Solid Tumors. J. Clin. Oncol. 33, 3541\u20133543 (2015).","journal-title":"J. Clin. Oncol."},{"key":"12794_CR43","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/nature10358","volume":"477","author":"CJ Breitbach","year":"2011","unstructured":"Breitbach, C. J. et al. Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans. Nature 477, 99\u2013102 (2011).","journal-title":"Nature"},{"key":"12794_CR44","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.cell.2012.08.040","volume":"151","author":"AH Chau","year":"2012","unstructured":"Chau, A. H., Walter, J. M., Gerardin, J., Tang, C. & Lim, W. A. Designing synthetic regulatory networks capable of self-organizing cell polarization. Cell 151, 320\u2013332 (2012).","journal-title":"Cell"},{"key":"12794_CR45","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","volume":"377","author":"JD Wolchok","year":"2017","unstructured":"Wolchok, J. D. et al. Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. N. Engl. J. Med. 377, 1345\u20131356 (2017).","journal-title":"N. Engl. J. Med."},{"key":"12794_CR46","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.ejca.2016.02.025","volume":"60","author":"L Hofmann","year":"2016","unstructured":"Hofmann, L. et al. Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy. Eur. J. Cancer 60, 190\u2013199 (2016).","journal-title":"Eur. J. Cancer"},{"key":"12794_CR47","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1038\/nature24649","volume":"552","author":"T Wartewig","year":"2017","unstructured":"Wartewig, T. et al. PD-1 is a haploinsufficient suppressor of T cell lymphomagenesis. Nature 552, 121\u2013125 (2017).","journal-title":"Nature"},{"key":"12794_CR48","doi-asserted-by":"publisher","first-page":"6429","DOI":"10.1158\/0008-5472.CAN-17-1662","volume":"77","author":"Y Guo","year":"2017","unstructured":"Guo, Y. et al. Multiscale modeling of inflammation-induced tumorigenesis reveals competing oncogenic and oncoprotective roles for inflammation. Cancer Res. 77, 6429\u20136441 (2017).","journal-title":"Cancer Res."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-019-12794-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-019-12794-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-019-12794-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,16]],"date-time":"2022-12-16T20:50:21Z","timestamp":1671223821000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-019-12794-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,22]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["12794"],"URL":"https:\/\/doi.org\/10.1038\/s41467-019-12794-2","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,22]]},"assertion":[{"value":"21 February 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare competing interests as following: Z.X., H.H. W.L. and Y.L. are shareholders of Syngentech Inc; Z.X., H.H., Y.L. and W.L. have filed a patent application (PCT\/CN2017\/096043) to State Intellectual Property Office of China based on the findings in this work. Tsinghua University and Syngentech Inc. are the patent applicants. Z.X., H.H., Y.L. and W.L. are the co-inventors. The patent describes the application of mutual inhibition gene circuit in oncolytic adenovirus in the manuscript.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4801"}}